On June 12, Merck rose 3.03% in regular trading, trading at $122.635/share, with turnover of $946 million. The stock continued its upward momentum driven by a series of positive pipeline developments over recent days.

On the news front, Merck's 9-valent HPV vaccine recently received approval from China's National Medical Products Administration to expand its eligible population from ages 16-26 to 9-45 for women, significantly broadening its addressable market as the only commercially available 9-valent HPV vaccine globally. Additionally, Merck and Gilead Sciences announced that two Phase 3 trials of their combination HIV pill containing islatravir and lenacapavir met primary endpoints, demonstrating non-inferiority to the current standard of care. Meanwhile, Merck launched sotatercept in China for pulmonary arterial hypertension, addressing an unmet medical need, and a company executive confirmed that the priority review voucher for Enlicitide is progressing smoothly.

Within the Pharmacy sector, the overall sector showed broad gains. Among individual stocks, Pfizer up 2.8%, Eli Lilly up 2.68%, Novo-Nordisk up 2.64%, Johnson & Johnson up 0.83%, Zoetis up 0.17%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)